期刊文献+

肺炎支原体肺炎临床治疗探讨 被引量:3

Study on clinical treatment of mycoplasmal pneumonia
暂未订购
导出
摘要 目的探讨肺炎支原体肺炎的临床治疗。方法①退热治疗:阿司匹林0.5g,放入100ml温水中冲服,3~5h后可重复应用。②抗感染治疗:常用药物是红霉素,成人500mg口服,1次/6h,8岁以下儿童给予红霉素每日30~50mg/kg。③镇咳祛痰治疗:用痰热清进行静脉滴注,1次/d,每次使用剂量为10ml,持续治疗5d。结果75例肺炎支原体肺炎患者经过治疗后,治愈56例,显效13例,无效6例,总有效率92%。结论本文中,75例患者经过退热治疗、抗感染治疗、镇咳祛痰治疗后,总有效率92%,治疗总有效率较高,治疗方法值得临床参考借鉴。 Objective To evaluate the clinical treatment of mycoplasmal pneumonia. Methods Fever treatment: taken 0. 5 g aspirin after it mixed with 100 ml warm water; application could be repeated after 3 ~ 5 h. Anti infection treatment : commonly used drug is erythromycin. 500 mg per 6 hours for adults and 30 .- 50 mg/kg per day for children under 8 years. Antitussive and expectorant treatment: intravenous infusion with Tan- reqing once a day, each time with a dose of 10 ml, continued for 5 days. Results Among the 75 cases of my- coplasmal pneumonia patients after treatment, 56 cases were cured, 13 cases were effective, and 6 cases were ineffective. The total effective rate was 92%. Conclusion In this article, 75 patients with mycoplasmal pneu- monia were treated with fever treatment, anti infection treatment, and antitussive and expectorant treatment; the total effective rate was 92%. The effective rate is relatively high and the treatment method is worthy of clinical reference.
作者 柏文彦
出处 《中国现代药物应用》 2013年第23期152-153,共2页 Chinese Journal of Modern Drug Application
关键词 肺炎支原体肺炎 Mycoplasmal pneumonia
  • 相关文献

参考文献6

二级参考文献29

  • 1郑匀江.3种方案治疗消化性溃疡幽门螺杆菌感染药物经济学分析[J].中国医院药学杂志,2005,25(9):883-884. 被引量:13
  • 2Waites KB,Talkington DF.Mycoplasma pneumoniae and its role as a human pathogen[J].Clin Mierobiol Rev,2004,17(4):697-728.
  • 3Chaudhry R,Varahney AK,Malhotra P.Adhesion proteins of Mycoplas ma pneumoniae[J].Front Biosci,2007,12:690-699.
  • 4Yavlovich A,Tarshis M,Rottem S.Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells[J].FEMS Microbiol Lett,2004,233(2):241-246.
  • 5Kannan TR,Provenzano D,Wright JR,et al.Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae[J].Infect Immun,2005,73 (5):2828-2834.
  • 6Kannan TR,Baseman JR.ADP-ribosylating and vacuolating eytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens[J].Proc Nail Acad Sci USA,2006,103 (17):6724-6729.
  • 7Kunnan TR,Provenzano D,Wright JR,et al.Identification and characterization of human surfactant protein A binging protein of Mycoplasma pneumoniae[J].Infect Immun,2005,73(5):2828-2834.
  • 8Shimizu T,Kida Y,Kuwano K.A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1,TLR2 and TLR6[J].J Immunol,2005,175(7):4641-4646.
  • 9Into T,Kiura K,Yasuda M.et al.Stimulation of human Tolllike receptor (TLR)2 and TLR6 with membrane lipoproteins of Mycoplasma fementans induces apoptotic cell death after NFkappa B activation[J].Cell Microbiol,2004.6(2):187-199.
  • 10Stelmach I,Podsiodlowicz-Borzeka M,Grzelewski T,et al.Humoral and cellular immunity in children with Mycoplasma pneumoniae infection:a 1-year prospective study[J].Clin Diagn Lab Immunol,2005,12(10):1246-1250.

共引文献164

同被引文献14

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部